Strategies to manage hepatitis C virus infection disease burden – volume 3
Authors:
Open Access
- 29 October 2015
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 22 (S4) , 42-65
Abstract
Summary: The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries in Europe, the Middle East and Asia, and the relative impact of two scenarios was considered: increased treatment efficacy while holding the annual number of treated patients constant and increased treatment efficacy and an increased annual number of treated patients. Increasing levels of diagnosis and treatment, in combination with improved treatment efficacy, were critical for achieving substantial reductions in disease burden. A 90% reduction in total HCV infections within 15 years is feasible in most countries studied, but it required a coordinated effort to introduce harm reduction programmes to reduce new infections, screening to identify those already infected and treatment with high cure rate therapies. This suggests that increased capacity for screening and treatment will be critical in many countries. Birth cohort screening is a helpful tool for maximizing resources. Among European countries, the majority of patients were born between 1940 and 1985. A wider range of birth cohorts was seen in the Middle East and Asia (between 1925 and 1995).Keywords
Funding Information
- Gilead Sciences
This publication has 14 references indexed in Scilit:
- The present and future disease burden of hepatitis C virus infections with today's treatment paradigm – volume 3Journal of Viral Hepatitis, 2015
- Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 3Journal of Viral Hepatitis, 2015
- The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm – volume 2Journal of Viral Hepatitis, 2015
- The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigmJournal of Viral Hepatitis, 2014
- Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirationsGeneral Hospital Psychiatry, 2013
- Total Numbers of Undiagnosed Carriers of Hepatitis C and B Viruses in Japan Estimated by Age- and Area-Specific Prevalence on the National ScaleIntervirology, 2011
- Epidemiology of hepatocellular carcinoma in JapanJournal of Gastroenterology, 2009
- High Deferral Rates and Poorer Treatment Outcomes for HCV Patients with Psychiatric and Substance Use ComorbiditiesDigestive Diseases and Sciences, 2007
- Barriers to the treatment of hepatitis CJournal of General Internal Medicine, 2005
- A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decadesProceedings of the National Academy of Sciences, 2002